DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Mitomycin - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Antibiotics, Antineoplastic
  • Alkylating Agents
  • Cross-Linking Reagents
  • Nucleic Acid Synthesis Inhibitors

Dosage Forms

  • Injection (5, 20, 40 mg/vial)

Brands / Synonyms

-methoxymitosane; 7-Amino-9α Ametycin; Ametycine; Mit-C; Mitamycin; Mito-C; Mitocin-C; Mitomycin; Mitomycin (TN); Mitomycin (USAN); Mitomycin C; Mitomycin C (JP14); Mitomycin C/NaCl; Mitomycin [USAN:BAN:INN]; Mitomycin-C; Mitomycinum; Mitomycinum C; Mitomycyna C [Polish]; Mitosol; Mitozytrex; MMC; Muamycin; Muamycin (TN); Mutamycin; Mytomycin; Mytozytrex

Indications

For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder.

Pharmacology

Mitomycin is one of the older chemotherapy drugs, which has been around and in use for decades. It is an antibiotic which has been shown to have antitumor activity. Mitomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Mitomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.

Mechanism of Action

Mitomycin is activated in vivo to a bifunctional and trifunctional alkylating agent. Binding to DNA leads to cross-linking and inhibition of DNA synthesis and function. Mitomycin is cell cycle phase-nonspecific.

Absorption

Erratic.

Toxicity

Oral, mouse: LD50 = 23 mg/kg; Oral, rat: LD50 = 30 mg/kg. Symptoms of overdose include nausea and vomiting.

Biotrnasformation / Drug Metabolism

Primarily hepatic, some in various other tissues.

Contraindications

Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes.

Drug Interactions

No information provided.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017